Investor Relations

Recent Event

Evercore ISI HealthCONx Conference

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Sign Up For Email Alerts

Receive updates straight into your inbox

Company Overview

Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Our proprietary Cabaletta Approach to B cell Ablation (CABA™) platform is designed to provide deep, durable and potentially curative responses with one-time administration, with the possibility of eliminating the need for chronic immune suppressive therapies. The CABA™ platform has potential applicability across dozens of B cell-mediated autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, myositis, systemic sclerosis, pemphigus vulgaris and myasthenia gravis. It encompasses both the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach as well as Cabaletta’s proprietary Chimeric AutoAntibody Receptor T (CAART) cells. Our lead CARTA candidate, CABA-201, is a 4-1BB-containing CD19-CAR T cell therapy based on a clinically evaluated fully human CD19 binder with a strong safety profile. CABA-201 is currently under development for autoimmune diseases with high unmet need. Our proprietary CAART cells are designed to selectively bind and eliminate the pathogenic B cells that express disease-causing autoantibodies while sparing normal B cells. Through our CABA™ platform, we have discovered and developed seven product candidates, including our clinical-stage therapies for patients with mucosal pemphigus vulgaris and MuSK myasthenia gravis. We hold multiple agreements with the University of Pennsylvania and other academic institutions to develop engineered T cell therapies. Our goal is to leverage our team’s expertise in autoimmunity and T cell therapy and our network of collaborators to rapidly discover and develop our portfolio of engineered T cell therapy candidates to transform the treatment of autoimmune diseases.

Investor Contact Information

Company

Cabaletta Bio, Inc.
2929 Arch Street
Suite 600
Philadelphia, PA 19104

Investor Relations

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

Stern Investor Relations, Inc.
Sarah McCabe
sarah.mccabe@sternir.com

Transfer Agent

American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8200 x4801
help@astfinancial.com
www.astfinancial.com